Time to recurrence and survival in serous ovarian tumors predicted from integrated genomic profiles

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Mankoo, Parminder K ^a   Shen, Ronglai ^a   Schultz, Nikolaus ^a   Levine, Douglas A ^a   Sander, Chris ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MESSENGER RNA; MICRORNA; PROTEIN P53;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PREDICTION; PROBABILITY; PROGNOSIS; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; RNA ANALYSIS; VALIDATION STUDY; GENETICS; MIDDLE AGED; MUTATION; OVARY TUMOR; PATHOLOGY; RECURRENT DISEASE; SURVIVAL;

DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PROGNOSIS; RECURRENCE; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80455125871     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024709     Document Type: Article

References (45)

1. TCGA (2011) Integrated Genomic Analyses of Ovarian Carcinoma. Nature 474: 609-615.
2. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, et al. (2007) An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 25: 517-525.
3. Yoshihara K, Tajima A, Yahata T, Kodama S, Fujiwara H, et al. (2010) Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS One 5: e9615.
4. Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, et al. (2008) A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 68: 5478-5486.
5. Crijns AP, Fehrmann RS, de Jong S, Gerbens F, Meersma GJ, et al. (2009) Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med 6: e24.
6. Ein-Dor L, Kela I, Getz G, Givol D, Domany E, (2005) Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 21: 171-178.
7. Zou H, Hastie T, (2005) Regularization and variable selection via the elastic net. J R Statist Soc B 67: 301-320.
8. Helleman J, Smid M, Jansen MP, van der Burg ME, Berns EM, (2010) Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture. Gynecol Oncol 117: 170-176.
9. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, et al. (2005) Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 11: 2149-2155.
10. Schramm A, Schulte JH, Klein-Hitpass L, Havers W, Sieverts H, et al. (2005) Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 24: 7902-7912.
11. Park MY, Hastie T, (2007) L1-regularization path algorithm for generalized linear models. J R Statist Soc B 69: 659-677.
12. IPA Ingenuity Pathway Analysis. Available: http://www.ingenuity.com. Accessed 2011 Sep 30.
13. Maere S, Heymans K, Kuiper M, (2005) Bingo: a Cytoscape plugin to assess overrepresentation of Gene Ontology categories in Biological Networks. Human Molecular Genetics 21: 3448-3449.
14. Lopes CT, Franz M, Kazi F, Donaldson SL, Morris Q, et al. (2010) Cytoscape Web: an interactive web-based network browser. Bioinformatics 26: 2347-2348.
15. Cerami E, Demir E, Schultz N, Taylor BS, Sander C, (2010) Automated network analysis identifies core pathways in glioblastoma. PLoS One 5: e8918.
16. Rajan JV, Wang M, Marquis ST, Chodosh LA, (1996) Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. Proc Natl Acad Sci U S A 93: 13078-13083.
17. L'Esperance S, Bachvarova M, Tetu B, Mes-Masson AM, Bachvarov D, (2008) Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics 9: 99.
18. Peluso JJ, Gawkowska A, Liu X, Shioda T, Pru JK, (2009) Progesterone receptor membrane component-1 regulates the development and Cisplatin sensitivity of human ovarian tumors in athymic nude mice. Endocrinology 150: 4846-4854.
19. Causey MW, Huston LJ, Harold DM, Charaba CJ, Ippolito DL, et al. (2011) Transcriptional Analysis of Novel Hormone Receptors PGRMC1 and PGRMC2 as Potential Biomarkers of Breast Adenocarcinoma Staging. J Surg Res doi:10.1016/j.jss.2010.04.034.
20. Wu ZZ, Lu HP, Chao CC, (2010) Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells. Biochem Pharmacol 80 (2): 262-276.
21. Wada S, Noguchi T, Takeno S, Kawahara K, (2006) PIK3CA and TFRC located in 3q are new prognostic factors in esophageal squamous cell carcinoma. Ann Surg Oncol 13: 961-966.
22. Awasthi S, Singhal SS, Sharma R, Zimniak P, Awasthi YC, (2003) Transport of glutathione conjugates and chemotherapeutic drugs by RLIP76 (RALBP1): a novel link between G-protein and tyrosine kinase signaling and drug resistance. Int J Cancer 106: 635-646.
23. Tan AC, Jimeno A, Lin SH, Wheelhouse J, Chan F, et al. (2009) Characterizing DNA methylation patterns in pancreatic cancer genome. Mol Oncol 3: 425-438.
24. Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, et al. (2009) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113: 1315-1325.
25. Poroyo V, Birukona A, (2007) ARHGEF2 (rho/rac guanine nucleotide exhange factor). Atlas Genet Cytogenet Oncol Haematol 11: 58-59.
26. Mizuarai S, Yamanaka K, Kotani H, (2006) Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Cancer Res 66: 6319-6326.
27. Noetzel E, Veeck J, Horn F, Hartmann A, Knuchel R, et al. (2008) [Promoter methylation of ID4. A marker for recurrence-free survival in human breast cancer]. Pathologe 29 (Suppl 2): 319-327.
28. Dell'Orso S, Ganci F, Strano S, Blandino G, Fontemaggi G, (2010) ID4: a new player in the cancer arena. Oncotarget 1: 48-58.
29. Borden KL, (2000) RING domains: master builders of molecular scaffolds? J Mol Biol 295: 1103-1112.
30. Freemont PS, (2000) RING for destruction? Curr Biol 10: R84-87.
31. Tai YT, Soydan E, Song W, Fulciniti M, Kim K, et al. (2009) CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood 113: 4309-4318.
32. Ota T, Gilks CB, Longacre T, Leung PC, Auersperg N, (2007) HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features. Reprod Sci 14: 605-614.
33. Zangenberg M, Grubach L, Aggerholm A, Silkjaer T, Juhl-Christensen C, et al. (2009) The combined expression of HOXA4 and MEIS1 is an independent prognostic factor in patients with AML. Eur J Haematol 83: 439-448.
34. Yu SY, Chan DW, Liu VW, Ngan HY, (2009) Inhibition of cervical cancer cell growth through activation of upstream kinases of AMP-activated protein kinase. Tumour Biol 30: 80-85.
35. Subramanian J, Simon R, (2010) An evaluation of resampling methods for assessment of survival risk prediction in high-dimensional settings. Statist Med 30: 642-653.
36. Bovelstad HM, Nygard S, Storvold HL, Aldrin M, Borgan O, et al. (2007) Predicting survival from microarray data-a comparative study. Bioinformatics 23: 2080-2087.
37. Heller G, Simonoff JS, (1992) Prediction in Censored Survival Data: A comparison of the Proportional Hazards and Linear Regression Models. Biometrics 48: 101-115.
38. Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, et al. (2002) Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20: 3972-3982.
39. Slovin SF, Wilton AS, Heller G, Scher HI, (2005) Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin Cancer Res 11: 8669-8673.
40. Tibshirani R, (1997) The lasso method for variable selection in the Cox model. Stat Med 16: 385-395.
41. GÖnen M, Heller G, (2005) Concordance probability and discriminatory power in proportional hazards regression. Biometrika 92: 965-970.
42. Daemen A, Gevaert O, Ojeda F, Debucquoy A, Suykens JA, et al. (2009) A kernel-based integration of genome-wide data for clinical decision support. Genome Med 1: 39.
43. Witten DM, Tibshirani RJ, (2009) Extensions of sparse canonical correlation analysis with applications to genomic data. Stat Appl Genet Mol Biol 8: Article28.
44. Shen R, Olshen AB, Ladanyi M, (2009) Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics 25: 2906-2912.
45. Pavlidis P, Weston J, Cai J, Noble WS, (2002) Learning gene functional classifications from multiple data types. J Comput Biol 9: 401-411.